Ollikainen M, Hannelius U, Lindgren C M, Abdel-Rahman W M, Kere J, Peltomäki P
Department of Medical Genetics, University of Helsinki, Helsinki, Finland.
Oncogene. 2007 Jul 5;26(31):4541-9. doi: 10.1038/sj.onc.1210236. Epub 2007 Jan 29.
Mutations in the DNA mismatch repair gene MLH1 are a major cause of hereditary nonpolyposis colorectal cancer (HNPCC). No mutant phenotype is observed before the wild-type (wt) allele is somatically inactivated in target tissue. We addressed the mechanisms of MLH1 inactivation in 25 colorectal (CRC) and 32 endometrial cancers (ECs) from MLH1 mutation carriers (Mut1, in-frame genomic deletion; Mut2, out-of-frame splice site mutation; Mut3, missense mutation). By a quantitative method, matrix-assisted laser desorption/ionization-time-of-flight (MALDI-TOF), utilizing four intragenic single nucleotide polymorphisms and mutations, loss of heterozygosity (LOH) was present in 31/57 (54.4%) of tumors. The wt allele displayed LOH more often than the mutant allele (23/57 vs 8/57, P=0.006). For Mut1, LOH was more frequent in CRC than EC (10/11 vs 1/13, P<0.0001), whereas Mut2 and Mut3 displayed opposite LOH pattern. Moreover, although wt LOH predominated in CRC irrespective of the predisposing mutation, LOH often affected the mutant allele in EC from Mut2 and Mut3 carriers (6/19, 31.6%). MLH1 promoter methylation, which reflected a more widespread hypermethylation tendency, occurred in 4/55 (7.3%) of tumors and was inversely associated with LOH. In conclusion, the patterns of somatic events (LOH and promoter methylation) differ depending on the tissue and germline mutation, which may in part explain the differential tumor susceptibility of different organs in HNPCC. MALDI-TOF provides a novel approach for the detection and quantification of LOH.
DNA错配修复基因MLH1的突变是遗传性非息肉病性结直肠癌(HNPCC)的主要病因。在野生型(wt)等位基因在靶组织中发生体细胞失活之前,未观察到突变表型。我们研究了来自MLH1突变携带者(Mut1,框内基因组缺失;Mut2,框外剪接位点突变;Mut3,错义突变)的25例结直肠癌(CRC)和32例子宫内膜癌(EC)中MLH1失活的机制。通过一种定量方法,即利用四个基因内单核苷酸多态性和突变的基质辅助激光解吸/电离飞行时间(MALDI-TOF),57个肿瘤中有31个(54.4%)出现杂合性缺失(LOH)。wt等位基因比突变等位基因更常出现LOH(23/57 vs 8/57,P = 0.006)。对于Mut1,CRC中LOH比EC更常见(10/11 vs 1/13,P < 0.0001),而Mut2和Mut3表现出相反的LOH模式。此外,尽管无论易感突变如何,wt LOH在CRC中占主导,但在Mut2和Mut3携带者的EC中,LOH常影响突变等位基因(6/19,31.6%)。MLH1启动子甲基化反映了更广泛的高甲基化趋势,在55个肿瘤中有4个(7.3%)出现,且与LOH呈负相关。总之,体细胞事件(LOH和启动子甲基化)的模式因组织和种系突变而异,这可能部分解释了HNPCC中不同器官的肿瘤易感性差异。MALDI-TOF为LOH的检测和定量提供了一种新方法。